Lung Adenocarcinoma - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 92 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Lung Adenocarcinoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Lung Adenocarcinoma - Pipeline Review, H2 2014', provides an overview of the Lung Adenocarcinoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lung Adenocarcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Adenocarcinoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lung Adenocarcinoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Lung Adenocarcinoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Lung Adenocarcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lung Adenocarcinoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lung Adenocarcinoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lung Adenocarcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Lung Adenocarcinoma Overview 8
Therapeutics Development 9
Pipeline Products for Lung Adenocarcinoma - Overview 9
Pipeline Products for Lung Adenocarcinoma - Comparative Analysis 10
Lung Adenocarcinoma - Therapeutics under Development by Companies 11
Lung Adenocarcinoma - Therapeutics under Investigation by Universities/Institutes 13
Lung Adenocarcinoma - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Lung Adenocarcinoma - Products under Development by Companies 17
Lung Adenocarcinoma - Products under Investigation by Universities/Institutes 18
Lung Adenocarcinoma - Companies Involved in Therapeutics Development 19
Amgen Inc. 19
Astex Pharmaceuticals, Inc. 20
AstraZeneca PLC 21
Axelar AB 22
Bayer AG 23
BioNumerik Pharmaceuticals, Inc. 24
Boehringer Ingelheim GmbH 25
Genentech, Inc. 26
Genmab A/S 27
Hanmi Pharmaceuticals, Co. Ltd. 28
Immunomedics, Inc. 29
Medisyn Technologies, Inc. 30
Pfizer Inc. 31
Sanofi 32
VG Life Sciences, Inc. 33
Vichem Chemie Research Ltd. 34
Lung Adenocarcinoma - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Target 37
Assessment by Mechanism of Action 40
Assessment by Route of Administration 42
Assessment by Molecule Type 44
Drug Profiles 46
afatinib - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AXL-1717 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
AZD-6738 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
BAY-1163877 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Cell Therapy to Activate CD40L and GM-CSF for Metastatic Lung Cancer and Lung Adenocarcinoma - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
dacomitinib - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
DBPR-112 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
dimesna - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
hydroxychloroquine + sorafenib tosylate - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Interferon Lambda-1 Linked Fab Dimer - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
MAG-Tn3 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
MT-477 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
poziotinib - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
SAR-408701 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Small Molecule for Cancer - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Small Molecule to Inhibit EGFR for Oncology - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecules for Lung Adenocarcinoma - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Small Molecules to Activate PKM2 for Lung Adenocarcinoma - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Small Molecules to Inhibit Lactate Dehydrogenase for Lung Adenocarcinoma - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
SNX-5422 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
solitomab - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Stem Cell Therapy for Oncology - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
TF-011 Monomethyl Auristatin E - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Lung Adenocarcinoma - Recent Pipeline Updates 79
Lung Adenocarcinoma - Dormant Projects 90
Appendix 91
Methodology 91
Coverage 91
Secondary Research 91
Primary Research 91
Expert Panel Validation 91
Contact Us 92
Disclaimer 92

List of Tables
Number of Products under Development for Lung Adenocarcinoma, H2 2014 9
Number of Products under Development for Lung Adenocarcinoma - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Lung Adenocarcinoma - Pipeline by Amgen Inc., H2 2014 19
Lung Adenocarcinoma - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 20
Lung Adenocarcinoma - Pipeline by AstraZeneca PLC, H2 2014 21
Lung Adenocarcinoma - Pipeline by Axelar AB, H2 2014 22
Lung Adenocarcinoma - Pipeline by Bayer AG, H2 2014 23
Lung Adenocarcinoma - Pipeline by BioNumerik Pharmaceuticals, Inc., H2 2014 24
Lung Adenocarcinoma - Pipeline by Boehringer Ingelheim GmbH, H2 2014 25
Lung Adenocarcinoma - Pipeline by Genentech, Inc., H2 2014 26
Lung Adenocarcinoma - Pipeline by Genmab A/S, H2 2014 27
Lung Adenocarcinoma - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 28
Lung Adenocarcinoma - Pipeline by Immunomedics, Inc., H2 2014 29
Lung Adenocarcinoma - Pipeline by Medisyn Technologies, Inc., H2 2014 30
Lung Adenocarcinoma - Pipeline by Pfizer Inc., H2 2014 31
Lung Adenocarcinoma - Pipeline by Sanofi, H2 2014 32
Lung Adenocarcinoma - Pipeline by VG Life Sciences, Inc., H2 2014 33
Lung Adenocarcinoma - Pipeline by Vichem Chemie Research Ltd., H2 2014 34
Assessment by Monotherapy Products, H2 2014 35
Assessment by Combination Products, H2 2014 36
Number of Products by Stage and Target, H2 2014 38
Number of Products by Stage and Mechanism of Action, H2 2014 41
Number of Products by Stage and Route of Administration, H2 2014 43
Number of Products by Stage and Molecule Type, H2 2014 45
Lung Adenocarcinoma Therapeutics - Recent Pipeline Updates, H2 2014 79
Lung Adenocarcinoma - Dormant Projects, H2 2014 90